Media stories about Tabula Rasa HealthCare (NASDAQ:TRHC) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tabula Rasa HealthCare earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.3727811998741 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
NASDAQ TRHC opened at $52.23 on Friday. Tabula Rasa HealthCare has a twelve month low of $12.63 and a twelve month high of $54.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.41 and a current ratio of 0.45. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -1,305.75, a PEG ratio of 4.73 and a beta of 2.38.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Tuesday, May 8th. The company reported $0.10 EPS for the quarter. Tabula Rasa HealthCare had a negative net margin of 0.61% and a positive return on equity of 0.38%. The business had revenue of $43.94 million for the quarter, compared to analysts’ expectations of $42.60 million. During the same period in the previous year, the company posted $0.08 EPS. Tabula Rasa HealthCare’s revenue was up 57.0% on a year-over-year basis. equities analysts expect that Tabula Rasa HealthCare will post 0.45 earnings per share for the current year.
Several research firms have weighed in on TRHC. MED lifted their price objective on shares of Tabula Rasa HealthCare from $47.00 to $63.00 and gave the stock an “outperform” rating in a research report on Monday, May 21st. Piper Jaffray Companies reiterated an “overweight” rating and set a $46.00 price objective on shares of Tabula Rasa HealthCare in a research report on Wednesday, May 9th. BidaskClub cut shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. CIBC reiterated an “outperform” rating and set a $47.00 price objective (up from $35.00) on shares of Tabula Rasa HealthCare in a research report on Tuesday, March 13th. Finally, Zacks Investment Research cut shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research report on Saturday, March 17th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $43.33.
In related news, Director Bruce Luehrs sold 85,842 shares of the company’s stock in a transaction on Tuesday, May 22nd. The shares were sold at an average price of $50.66, for a total value of $4,348,755.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $35.59, for a total transaction of $284,720.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 265,600 shares of company stock worth $12,312,120. 14.00% of the stock is currently owned by corporate insiders.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.